Please ensure JavaScript is enabled for purposes of website accessibility Request a Representative | TEPEZZA® (teprotumumab-trbw) for HCPs

You are now leaving the site

Are you sure you want to leave?

CANCEL LEAVE

Sign Up Receive the latest news and updates about TEPEZZA

Request an AMGEN Representative

The TEPEZZA support team is available to address your questions and provide information via email

Enter your information below to connect with a member of the TEPEZZA team. All fields are required.

Choose to be contacted by at least 1 support resource:


Specialty Account Manager (SAM): The SAM is your primary point of contact for TEPEZZA. Your SAM provides clinical education and resources for you and your office. In addition, your SAM will connect you to all TEPEZZA team members as specific needs arise.

Regional Medical Director (RMD): The RMD is a field-based clinical and medical expert (PharmD, PhD, MD, or OD) on Amgen medicines.

Patient Access Liaison (PAL): The PAL provides dedicated, one-on-one support for your patient. They work directly with individual patients to answer non-medical, logistical questions and provide support upon enrollment. Additionally, the PAL educates your patients on how to navigate the insurance process and access treatment on your patient's behalf. The PAL has the expertise and tools to support the patient by educating on patient benefits, prior authorization requirements, payor policies, and coding and claim submissions.


Please select at least one.

*Required field

Personal Information

(You can expedite the sign-up process by entering your number)

Please enter your NPI.
Please enter your first name.
Please enter your last name.
Please enter valid Phone Number
Please enter a 10-digit US phone number.
Please provide an email address. 
Please enter a valid email address. 

Office Address

Please enter your street address.
Please enter your city.
Please enter your state.
Please enter your ZIP Code.

Please enter valid address

Alternate address found. Please select one
Entered Address:
Suggested Address:
Please select your specialty.
Please enter number of patients.
I would like to receive email updates (optional).

Privacy Notice and Consent: I understand I am giving Amgen, its affiliates, and business partners permission to use the personal information provided in this registration form, as described in this authorization. I understand that the information I am providing may be used by Amgen to provide me with health and product information and related services concerning health conditions and treatments. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Amgen Terms & Conditions and Privacy Policy. I understand that Amgen and its contracted third parties will NOT sell or rent personal information, and that the information provided in this form will be used in accordance with the Amgen Privacy Policy. I agree that this authorization will expire ten (10) years from the date submitted, or until my participation in the program ends through my cancellation. I acknowledge that I am submitting this form voluntarily, and that I am at least 18 years of age.

Please agree.


IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Full Prescribing Information for more information.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions